... as Q2 Loss Widens on Declining Sales; Firm Cuts '06 Revenue Forecast | GenomeWeb
Cepheid’s Q2 revenue did not fall across the board as was originally reported; clinical product sales increased 135 percent during the period. Also, the company had around $80.5 million in marketable securities as of June 30.
NEW YORK (GenomeWeb News) – Cepheid yesterday reported a 7-percent drop in second-quarter revenues as products and services declined in most segments.
The news caused shares in the company to trade down 18.7 percent, or $1.62, to $7.05 mid-afternoon today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

In Nature this week: genetic history of HIV in the US, and more.